Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer

202040 citationsJournal Articlegold Open Access

Authors

Kyung Jin Eoh · Severance Hospital

Hye Min Kim · Yonsei University

Jung‐Yun Lee · Yonsei University

Sunghoon Kim · Yonsei University

Sang Wun Kim · Yonsei University

Young Tae Kim · Yonsei University

Eun Ji Nam · Yonsei University

Abstract

Somatic mutation analysis by next-generation sequencing, in addition to germline BRCA1/2 mutation analysis, should become the standard of care for managing women with high-grade serous ovarian cancer to widen the indication of poly (ADP-ribose) polymerase inhibitors.

Topics & Keywords

PARP inhibition in cancer therapy CRISPR and Genetic Engineering BRCA gene mutations in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMC Cancer

Volume 20, Issue 1, pp. 204-204

DOI: 10.1186/s12885-020-6693-y

Field-Weighted Citation Impact: 2.34